PBLS Parabilis Medicines, Inc.: institutional ownership and insider trading
85 funds reported holding $2.71B of Parabilis Medicines, Inc. in their latest 13F filings; in Q2 2026 funds net bought $2.65B, with 78 new positions and 0 funds selling out; over the last 12 months insiders bought $441M and sold $0 on the open market.
PBLS revenue and earnings
- Quarter ended Jun 30, 2026: revenue $148K, net income −$52.5M, EPS -2.32
- Quarter ended Mar 31, 2026: revenue n/a, net income −$45.3M
- Quarter ended Jun 30, 2025: revenue $0, net income −$34.8M, EPS -22.28
- Quarter ended Mar 31, 2025: revenue n/a, net income −$38.3M
Famous investors holding PBLS
- Two Sigma (Two Sigma Investments): $239K, 0.0% of the portfolio
Largest institutional holders of PBLS
- RA CAPITAL MANAGEMENT, L.P. — $792M
- FMR LLC — $282M
- ARCH Venture Management, LLC — $176M
- venBio Partners LLC — $144M
- Alphabet Inc. (GOOG, GOOGL) — $135M
- Nextech Invest, Ltd. — $128M
- Cormorant Asset Management, LP — $126M
- REGENERON PHARMACEUTICALS, INC. (REGN) — $114M
- Siren, L.L.C. — $81.9M
- FARALLON CAPITAL MANAGEMENT, L.L.C. — $64.8M
Recent PBLS insider trades
- Jul 22, 2026: RA Capital Healthcare Fund LP bought 244,593 shares ($6.92M)
- Jun 15, 2026: Sebulsky Alan bought 17,500 shares ($474K)
- Jun 11, 2026: Soleus Capital, LLC bought 500,000 shares ($10.0M)
- Jun 11, 2026: RA Capital Healthcare Fund LP bought 21,188,750 shares ($424M)
5%+ owners
- RA Capital Management, L.P.: 23.8% (Schedule 13D, filed Jun 18, 2026)
- FMR LLC: 8.5% (Schedule 13G, filed Aug 6, 2026)
- ARCH Venture Fund XII, L.P.: 5.3% (Schedule 13G, filed Aug 14, 2026)
Who owns the most PBLS stock?
The largest institutional holders of Parabilis Medicines, Inc. in the latest 13F filings are RA CAPITAL MANAGEMENT, L.P. ($792M), FMR LLC ($282M), ARCH Venture Management, LLC ($176M).
Are insiders buying or selling PBLS?
Over the last 12 months insiders bought $441M and sold $0 of Parabilis Medicines, Inc. stock on the open market (SEC Form 4).
Which famous investors own PBLS?
Two Sigma.
What was PBLS's revenue last quarter?
Parabilis Medicines, Inc. reported revenue of $148K for the quarter ended June 30, 2026, with net income of −$52.5M.
Which ETFs hold PBLS?
2 ETFs and mutual funds hold it among their top 100 positions, including JAGLX, FBDIX.